New hope for severe colitis: experimental drug BRS201 enters human testing
NCT ID NCT06420492
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 23 times
Summary
This study tests a new oral drug called BRS201 in 20 adults with severe ulcerative colitis who have not improved with standard treatments. Participants take the drug twice daily for 4 weeks and attend 8 clinic visits over 12 weeks. The goal is to see if BRS201 can reduce disease activity by targeting sulfur metabolism.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Brigham and Women's Hospital
NOT_YET_RECRUITINGChestnut Hill, Massachusetts, 02467, United States
-
Brigham and Women's Hospital
RECRUITINGChestnut Hill, Massachusetts, 02467, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.